SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalParadigm Genetics -- PDGM


Previous 10 
To: Mike McFarland who wrote (95)1/21/2006 11:50:28 AM
From: Mike McFarland
   of 101
 
CLDA "reorganizing into two operating divisions to be known
as Clinical Data Molecular and Vital Diagnostics. The
Clinical Data Molecular division will consolidate the
operations of Genaissance Pharmaceuticals, Inc., Lark
Technologies, Inc. and Icoria, Inc., all of which were
acquired by the Company during 2005. The Vital Diagnostics
division will consolidate the operations of Clinical Data
Sales and Service, Inc., Vital Scientific NV, Vital
Diagnostics Pty. Ltd., and Electa Lab s.r.l., the
Company’s previously owned subsidiaries in the small volume
clinical diagnostics market.

clda.com

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: Mike McFarland who wrote (97)1/24/2006 11:32:27 AM
From: Mike McFarland
   of 101
 
Clinical Data and IO Informatics
genomeweb.com
The $11.7-million grant was initially awarded to Clinical Data subsidiary Icoria in 2002

IO Informatics' intelligent multidimensional object
IMO will be applied to data accumulated through Clinical Data's Gene-to-Cell System

Share RecommendKeepReplyMark as Last Read


To: Mike McFarland who wrote (97)1/26/2006 11:30:26 AM
From: nigel bates
   of 101
 
Clinical Data Initiates Pivotal Phase III Trial for Novel Antidepressant
Thursday January 26, 8:00 am ET
First Ever Pharmacogenomic Screening Tool for Antidepressant to be Developed Concurrently
Maybe should have posted to the defunct Genaissance thread ?
Though this one seems more active...


NEWTON, Mass.--(BUSINESS WIRE)--Jan. 26, 2006--Clinical Data, Inc. (NASDAQ: CLDA - News), a worldwide leader in commercializing pharmacogenomics to guide drug utilization, announced today that the Company will begin enrollment of a pivotal Phase III clinical trial for vilazodone, a novel compound being studied for treatment of depression, and anticipates having initial results from this study available by mid-2007. The successful outcome of this trial would serve as one of two pivotal trials required for a new drug application ("NDA"), which the Company hopes to file with the United States Food & Drug Administration as early as year end 2008.

Carol R. Reed, M.D., the Company's Chief Medical Officer, said, "Following our recent meeting with the staff of the Division of Psychiatry Products of the FDA we are accelerating our development plans for vilazodone and a companion biomarker test. We believe this program has the potential to revolutionize the treatment of depression. As part of this trial, Clinical Data will use its expertise in biomarker discovery to identify biomarkers for response to vilazodone. We plan to use these biomarkers to develop a test to screen for patients who are likely to benefit from the drug. About half of depressed patients do not achieve satisfactory results with current first-line treatment options; we hope to assist physicians in matching a patient with a treatment that is likely to work for that patient. There are no such predictive tests currently available."

"This is a transformative event in the history of Clinical Data," said Clinical Data's President and CEO, Israel M. Stein, M.D. "The development of a genetic-based, predictive screening tool to guide the use of a novel antidepressant would represent a significant advance in pharmacogenomics and in the treatment of depression. While available therapeutics are many, a patient's response is highly individualized, leading to trial-and-error inefficiencies and unnecessary delay in finding effective treatment."

About Vilazodone

Vilazodone is a novel, dual serotonergic antidepressant. It is both a Selective Serotonin Reuptake Inhibitor (SSRI) and a 5HT1A partial agonist. The compound has been assessed in 15 phase I and five phase II trials involving a total of 369 healthy subjects and 1163 depressed patients. Vilazodone has been found to have an acceptable safety profile for this stage of development. In previous trials with positive controls, vilazodone failed to demonstrate significant efficacy against placebo but demonstrated efficacy comparable to that of the positive control, an approved antidepressant in wide use. The rights to develop and commercialize vilazodone were acquired from Merck KGaA of Darmstadt, Germany, in September 2004.

Clinical Trial Design

This double-blind, placebo-controlled clinical trial is designed to assess the efficacy and safety of vilazodone and to discover genetic markers of treatment response associated with vilazodone. The trial will enroll approximately 400 adult patients diagnosed with Major Depressive Disorder at eight US centers. Potential biomarkers will be examined for each clinical subject, and the genetic analysis will be performed in-house by the company at its GLP- and CLIA-approved facilities, which perform similar genetic services for many major pharmaceutical companies. At least one long-term safety study, which has yet to be reviewed by the FDA, will be required prior to NDA filing. The Company is hopeful that clinical subjects from each of the pivotal efficacy trials will participate in the long-term safety studies.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: nigel bates who wrote (99)1/26/2006 8:03:57 PM
From: Mike McFarland
   of 101
 
Scrappy company, CLDA!
Market Cap 149M, Enterprise Value 141M.

GLGC:
Market Cap 127M, Enterprise Value 38M

I guess if I was going to own one, I'd
choose the latter, but who knows.

It might be nice to see them merge, then
get swalloped up by a CRA with cash to burn.
I have to say however, if Covance or a Quintiles
or any big CROs had MC's of merely ~100M, I guess
they'd be on my watch lists too.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Mike McFarland who wrote (100)2/5/2006 12:25:25 PM
From: Mike McFarland
   of 101
 
CLDA is now at $25 and this looks like an all
time high--up 90% in the past year!

Well, I guess I should have held my Icoria and
gotten into this, it is really doing well. I will
start a thread for it on Monday if I can't find
one.

Share RecommendKeepReplyMark as Last Read
Previous 10